Fresenius Medical Care AG filed a Form 6-K with the SEC for the month of November 2026, covering its interim report of financial condition and results of operations for the three and nine months ended September 30, 2026 and 2025.
Key Highlights
- Pharmaceutical Business Reclassification: For the three and nine month periods ended September 30, 2026, certain pharmaceutical products business activities were reclassified from the Care Enablement segment to the Care Delivery segment, according to the filing.
- Comparative periods unchanged: The company disclosed that amounts for the three and nine months ended September 30, 2025 attributable to those reclassified activities "remain reported within Care Enablement and have not been reclassified."
- Value-Based Care integration: Beginning in April 2026, certain administrative functions for the Value-Based Care segment, including accounting, legal, compliance, human resources, and procurement, were incorporated into the company's global functional areas, with associated costs now allocated to the segment.
- ERP costs as corporate expenses: From January 1, 2026, project costs for implementing the company's new enterprise resource planning (ERP) software are reported as corporate expenses, the filing stated.
- Insurance accounting applied: Premiums and medical costs in full risk arrangements within the Value-Based Care segment are accounted for under IFRS 17, Insurance Contracts, with premium revenue and claim costs presented separately as insurance revenue and insurance costs of revenue.
- Reporting currency: The company uses the euro as its reporting currency, with financial statements prepared in accordance with IFRS as issued by the IASB.
Segment Structure Changes and Financial Reporting Updates at Fresenius Medical Care for Nine Months Ended September 30, 2026
Fresenius Medical Care AG submitted a Form 6-K to the SEC for the month of November 2026, containing its unaudited interim consolidated financial statements and management's discussion and analysis for the three and nine months ended September 30, 2026 and 2025. The company operates three segments: Care Enablement, Care Delivery, and Value-Based Care, according to the filing.
A notable change disclosed in the report is the Pharmaceutical Business Reclassification. The filing explained that "for the three and nine month periods ended September 30, 2026, these activities have been reclassified to the Care Delivery segment to reflect the global pharmaceutical business holistically within Care Delivery and changed responsibilities in how the business is organizationally managed at the chief operating decision maker level." The company noted that its "consolidated statements of income for the Company are unaffected" by this reclassification.
The filing also described changes to how the Value-Based Care segment is administered. Prior to April 2026, the segment "maintained its own separate finance, accounting, human resources, legal, medical office, and other administrative functions and was therefore excluded from the allocation process." Beginning in April 2026, several of those functions were folded into the company's global functional areas. Separately, ERP implementation costs have been classified as corporate expenses starting January 1, 2026. The report includes unaudited consolidated statements of income, balance sheets, statements of cash flows, and related notes, with quantitative and qualitative disclosures about market risk and controls and procedures also covered.
What Was Disclosed
Fresenius Medical Care AG filed a Form 6-K interim report covering the three and nine months ended September 30, 2026, disclosing segment reclassifications affecting the pharmaceutical business and Value-Based Care administrative integration, along with updated corporate expense treatment for ERP costs.




Please wait processing your request...